PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27054757-2	2016	Herein, we report one case of abnormal liver function tests occurring in a young HLA B*5701-negative woman on a stable nevirapine-based regimen with no history of liver problems or alcohol abuse after switching to abacavir from tenofovir.	Tenofovir	228-237	major histocompatibility complex, class I, B	Homo sapiens	81-86	
18784465-13	2008	CONCLUSION: Pharmacogenetic testing for HLA-B*5701 is cost-effective only if abacavir-based treatment is as effective and costs less than tenofovir-based treatment.	Tenofovir	138-147	major histocompatibility complex, class I, B	Homo sapiens	40-45